Imedex's Advances in Inflammatory Bowel Disease (AIBD) to Highlight Breaking Research

Share Article

Abstracts will be unveiled at world’s leading IBD meeting in Orlando this November

Imedex, a leading producer of medical education and a subsidiary of HMP, today announced a promising lineup of research abstracts will be presented during its 16th annual Advances in IBD (AIBD) Conference, November 9-11 in Orlando, Florida.

As the world’s largest and most influential multidisciplinary conference addressing the treatment and management of inflammatory bowel disease (IBD), AIBD brings together nearly 2,000 multidisciplinary healthcare professionals from across the globe to learn, share ideas, and discuss research and best practices to improve patient-centered care. IBD, which includes Crohn’s disease (CD) and ulcerative colitis (UC), is an increasing global health problem that affects as many as 5 million people around the world.

“AIBD 2017 serves as a unique global forum through which to examine the forefront of IBD research while engaging in stimulating discussion and exchange with peers from across the care spectrum,” said Miguel Regueiro, MD, FACG, a gastroenterologist with the University of Pittsburgh School of Medicine and one of three chairs for the conference. “The meeting delivers practical, clinical, and patient-centered insights over three days to accommodate the needs of today’s busy clinicians.”

Abstracts will be presented as posters during the conference and featured in a special supplement of the February 2018 issue of the American Journal of Gastroenterology. They include:

30-day Readmission After Ileal Pouch Anal Anastomosis Surgery: A Report from ACS-NSQIP Database
Aydinli H, et al; P-001

United States Claims Database Analysis Comparing Safety, Medical Resource Utilization, and Treatment Costs Associated with Management of Inflammatory Bowel Disease
Oh Y, et al; P-002

Improved Quality of Care for IBD Patients Using the HealthPROMISE App: A Randomized, Control Trial
Atreja A, et al: P-003

The Use of Alvimopan as Prophylaxis Against Postoperative Ileus After Bowel Resection in Patients with Inflammatory Bowel Disease
Jang J, et al; P-004

Cytomegalovirus Infection in Inflammatory Bowel Diseases in a Large, Single-center Cohort
Toruner M, et al; P-005

Psychiatric Characterization of Patients Enrolled in IBD Subspecialty Home
Weaver E, et al; P-006

Exposure-Response to SC Ustekinumab in Moderate–Severe Crohn’s Disease: Results from the IM-UNITI Maintenance Study
Adedokun O, et al; P-007

Relationship Between Vedolizumab Concentrations and Deep Remission in Patients With Moderately-to-Severely Active Ulcerative Colitis: A GEMINI 1 Post Hoc Analysis
Sandborn W, et al; P-008

Response and Remission After 16 Weeks of Ustekinumab – An All Patients Analysis from the UNITI Crohn’s Studies
Colombel JF, et al; P-009

Endoscopic and Clinical Efficacy Demonstrated with Oral Ozanimod in Active Crohn’s Disease in Biologic-Naïve and Biologic Experienced Patients
Feagan B, et al; P-010

Etrolizumab as Induction Therapy in Moderate to Severe Crohn’s Disease: Results From BERGAMOT Cohort 1
Sandborn W, et al; P-011

Ozanimod, an Oral S1P Receptor Modulator, is Effective and Well-tolerated in the Long-term Treatment of Moderate to Severe Ulcerative Colitis
Feagan B, et al; P-012

Pregnancy Outcomes in Women Exposed to Ustekinumab in the Crohn’s Disease Clinical Development Program
Scherl E, et al; P-013

Ustekinumab IV Induction Results in Crohn’s Disease Symptom Improvement Within the First Week in Anti-TNF Refractory Patients
Sandborn W, et al; P-014

Maintenance of Remission with Tofacitinib in Patients with Ulcerative Colitis: Subpopulation Analysis from an Open-Label, Long-Term Extension Study
Colombel JF, et al; P-015

Complications after Colonoscopy in Patients with Inflammatory Bowel Disease
Wang P, et al; P-016

Advanced Age is Associated with Decreased Long-term Functional Outcomes Following Ileal Pouch Anal Anastomosis
McKenna N, et al; P-017

Transabdominal Pouch Salvage for Failed Laparoscopic Ileal Pouch-Anal Anastomosis Aydinli H, et al; P-018

“We are pleased by the breadth of clinically relevant research that will be presented at this year’s Advances in IBD,” said Dan Lowrie, president, Imedex. “With scientific understanding advancing so rapidly, this research contributes to that momentum and to our attendees’ collective knowledge of IBD and will have a substantial impact on the current and future state of IBD care.”

To learn more about the meeting visit Media inquiries may be directed to Kelly McCurdy at pr(at)


Imedex is an industry leader in the creation of independent, accredited medical education for healthcare professionals that improves patient care around the world. With an emphasis in gastroenterology, hematology, and oncology, the company develops high-quality scientific programming that translates the latest research into clinically relevant information. Imedex provides more than 50,000 e-learning experiences annually and since 2001, its live conferences have welcomed more than 100,000 attendees. The company operates in the United States, Europe, and Asia. For more information, visit


HMP is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the healthcare community across a range of therapeutic areas. Its brands include Consultant, the monthly, award winning journal relied upon by primary care providers; Psych Congress, the largest independent mental health meeting in the U.S.; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP is supported by its lead investor, Susquehanna Growth Equity, LLC (SGE). For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kelly McCurdy
+1 610.560.0500 x4304 Ext: 4304
Email >
Follow us on
Visit website